Company forecasts 2026 revenue growth despite U.S. channel mix pressures, citing strong international demand and new product contributions.
Inogen outlined a 2026 revenue target of $355M-$361M and adjusted EBITDA of about $4M during its Q2 2026 earnings call. The guidance comes amid U.S. channel mix pressures but reflects optimism from international growth and new products like Voxi and Aurora Mask.
Q2 2026 revenue reached $95.1 million, up 3% year over year, driven by demand for portable oxygen concentrators and contributions from recent launches. The company highlighted strong performance in international markets as a key growth driver.
Management acknowledged challenges in the U.S. but emphasized strategic initiatives to stabilize domestic operations while expanding globally. The outlook assumes continued momentum in product adoption and operational efficiencies.